we are dedicated to our mission of making TTFields available to all cancer patients who may benefit from it.

Over a decade ago, we joined Novocure for the opportunity to make a meaningful difference in the lives of cancer patients. Establishing, building and growing an innovative company to provide patients with a new cancer treatment modality demands determination, perseverance and an unwavering focus on the scientific evidence to keep moving forward regardless of the obstacles or resistance that may be encountered. We are passionate about bringing our therapy to all patients who may benefit from it and to developing TTFields for additional solid tumor cancers.

Bill Doyle, Executive Chairman

Asaf Danziger, Chief Executive Officer